Redefining Synthetic Lethality
Tessellate BIO is redefining synthetic lethality in cancer beyond homologous recombination deficiency
![](https://tessellatebio.com/wp-content/uploads/2023/09/Tessellate_Bio_fullBlock_thin_greenBlue.png)
![](https://tessellatebio.com/wp-content/uploads/2023/09/Tessellate_Bio_fullBlock_thin_greenBlue.png)
Our vision
Our vision is to redefine synthetic lethality, turning cancer patients into cancer survivors.
Tessellate BIO's approach is unique
- Truly pioneering approach to synthetic lethality: tackling the areas of highest medical need through new targets beyond HRD
- Driven by profound scientific understanding: leading scientists as founders and key strategic advisors
- A ‘drug hunter’ model: bringing together best international science and proven drug development experience to create first-in-class pipeline
- Tumor agnostic: dependent on cancer genotype or phenotype rather than tissue of action
- Committed to precision medicine: companion diagnostics are integral, not an add-on
Our Team
An excellent blend of pharma and biotech R&D experience with a proven track record of drug development from patent to patient.
Our Science
We’re building a pipeline of first-in-class medicines based on cutting-edge research, sourced from international world-renowned laboratories
Would you like to know more?
Gooimeer 2-35 | 1411 DC Naarden | The_Netherlands
Privacy Policy – Terms & Conditions – Cookie policy
Privacy Policy – Terms & Conditions – Cookie policy
Tessellate Bio is a registered trademark of Tessellate Bio BV
Copyright ©2024 TessellateBIO BV All rights reserved.